Infinion Biopharma is a life sciences corporation that blends biophysics and engineering with classical pharmacology and biochemistry to develop high-value, unique medications in a variety of therapeutic domains. Infinion Biopharma IPO will hit the market in November 2021.
Table of Contents
About
They’ve built a global scientific ecosystem with a few of the globe ‘s greatest scientists from a variety of fields, such as biophysics, biochemistry, pharmacology, and biotechnology, to develop novel solutions to manage and treat a variety of conditions.
Their goal is to bring cutting-edge treatment options to India at the same time they become accessible in the developed world. In the past, India has fallen behind its developed-world competitors in the development of novel medicinal remedies.
They think that, given their worldwide scientific environment, they will be able to bridge the technical and time gaps, allowing Indians access to cutting-edge medical solutions.
Working Areas
They work in the pharmaceutical industry, licencing and commercialising high-value, innovative pharmaceuticals in a variety of therapeutic areas. The following are some of their current priority areas:
- Formulation Technology – to allow superior skin care and female’s health products; for this priority area, they have invested in and licenced technology from Ansella Therapeutics Inc. in the United States.
- Biotechnology – to provide better diagnostic and therapy options for neurological diseases; they have invested in Aurum Biosciences, based in the United Kingdom, for this key area.
- Process Technology – to enable better procedures for manufacturing biological pharmaceuticals; for this priority area, they intend to collaborate with Mobius Biomedical Inc., situated in the United States.
Plans
Due to the strong ties that their promoters have formed with those companies, they feel they have been capable to obtain attractive conditions for both obtaining licence rights and purchasing ownership in the above businesses.
They feel that acquiring licencing or investment in these highly wanted, innovative enterprises would have been more expensive for them or any other business in India if they didn’t have these contacts.
Furthermore, given their promoters’ strong ties to one of India’s major direct selling distribution networks, Vestige Marketing Pvt. Ltd., they may have exposure to a large distribution network in India.
Business model
They plan to offer a diaper rash treatment cream for newborns, adults, and a women’s healthcare cream for treating pre, peri, and post-menopausal disorders, for which they just inked a License Purchase deal.
These items would be produced by a contract manufacturer, and they would have sole rights to develop and market them in India for a minimum of ten years.
They also invest in early stage pharmaceutical research and technology development firms as part of their long-term stakeholder value creation strategy.
Their firm has currently invested in two biotechnology organizations: Ansella Therapeutics Inc. and Aurum Biosciences Ltd.
Infinion Biopharma IPO
Infinion Biopharma limited, headquartered in Ahmedabad has submitted Draft Red Herring Prospectus(DRHP) to Securities and Exchange Board of India(SEBI) for initial public offering (IPO) of 45,00,000 equity shares on 30 August, 2021.
The Offer doesn’t includes any fresh issue and an offer for sale(OFS) up to 45,00,000 equity shares of face value of 10 per share, by the promoters. Company will also consider at pre-IPO allotment of 7,00,000 equity shares.
They are now waiting for approval from Securities and Exchange Board of India(SEBI) to float the initial public offering (IPO) in the market.
Financials Trends
| Particulars | For the year ended ( in Lakhs) | ||
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |
| Total Assets | 1.83 | 0.86 | 0.75 |
| Total Revenue | 0.68 | 0 | 0 |
| Profit After Tax | 0.64 | (0.14) | (0.04) |
Basic and Diluted Earnings Per Share
| Financial Period | Basic EPS (in INR) | Diluted EPS (in INR) | Weight |
| Financial Year 2021 | 6.24 | 6.24 | 3 |
| Financial Year 2020 | (1.71) | (1.71) | 2 |
| Financial Year 2019 | (0.66) | (0.66) | 1 |
| Weighted Average | 0.94 | 0.89 |
Objects of the Issue
- Prepayment / repayment of all or a portion of the outstanding borrowings of the company to be availed on consolidated basis.
- To meet common corporate objectives.
Basis of The offer
The Issue Price is based on a number of qualitative characteristics and our strengths, which include:
- Promoters with years of expertise and extensive domain knowledge.
- Patented and Licensed Technology from Around the World.
- Collaborations with well-known manufacturers.
- Benefit to the first mover.
- Their track record of successful execution.
Infinion Biopharma IPO Peer Comparison
There are no publicly traded firms in India that operate in a similar industry to them. As a result, providing an industry comparison in regard to the company is not possible.
Infinion Biopharma IPO Details
| IPO Opening Date | November 2021 |
| IPO Closing Date | November 2021 |
| Issue Type | Book Building |
| Face Value | Rs. 10 per share |
| IPO Price | 0 to 0 per equity share |
| Market Lot | 0 |
| Min Order Quantity | 0 |
| Listing At | BSE, NSE |
| Issue Size | 45,00,000 Equity shares |
| Fresh Issue | – |
| Offer for Sale | 45,00,000 Equity shares |
Infinion Biopharma IPO Date
Infinion Biopharma IPO opening date is November 2021, and the closing date is November 2021. The issue may list on November 2021.
| IPO Open Date | November 2021 |
| IPO Close Date | November 2021 |
| Basis of Allotment Date | November 2021 |
| Initiation of Refunds | November 2021 |
| Credit of Shares to Demat Account | November 2021 |
| IPO Listing Date | November 2021 |
Basis of Allotment
| Type | % of Offer | Basis of Allotment |
|---|---|---|
| Qualified Institutional Buyer | 75 |
Roughly
equivalent
|
| Non Institutional Investor | 15 |
Roughly
equivalent
|
| Retail | 10 | Minimum level of 1 lot, based on availability, for every shareholder. |
Infinion Biopharma IPO Allotment Status
Allotment of equity stocks subject to the Fresh Issue and transfer of the Promoter Selling Shareholders’ OFS Stocks to the winning Bidders subject to the Offer for Sale. Nevertheless, the status of the allotment has yet to be revealed.
Here, you can find the Allotment Status of Infinion Biopharma IPO.
Infinion Biopharma IPO GMP
Infinion Biopharma IPO Grey Market Premium is 0. You can check out other IPOs GMP on below Links.
| Date | GMP (in Rs) | Subject to Sauda | Kostak (in Rs) |
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 | |||
| November 2021 |
Check Out the GMP of all Other IPOs
Infinion Biopharma IPO Review
Infinion Biopharma IPO review will depend on the price band. Whenever it will be announced we will update you regarding review of Infinion Biopharma IPO is good or bad.
Infinion Biopharma IPO Risk
- They’ve had a history of net losses in recent financials, and They expect higher expenses in the future.
- For product development and continued manufacturing of their licenced items, they are primarily reliant on third-party contract manufacturers.
- Their business may be considerably and negatively affected if their estimates or assumptions used in formulating their strategic strategy are incorrect.
- They do not own any of the land that the Firm uses for its activities.
- Their product development may not be as fruitful as they had hoped, or at all, resulting in product failure.
- One of their directors is currently involved in a law suit.
Other Threats
- Any negative change in regulatory regulations regulating the items they intend to market could hurt their business.
- Any disruption or shutdown of their contract manufacturers’ manufacturing facilities could have a negative impact on their business.
- They cannot guarantee the success of their past, present, or future efforts to commercialise business plans.
- Any product recall could have a negative impact on their business.
- For their continued services and strategic assistance, their Promoters and Senior Management are critical to their success.
- The COVID-19 pandemic, or any broad public health emergency, might have a significant and negative influence on their industry.
Promoters
- Gautam Bali
- Vishal Jain
- Govindsinh Chavada
Promoter Holding
| Pre Issue Share Holding | 54.78% |
| Post Issue Share Holding |
Infinion Biopharma IPO Prospectus
Contact Details
Infinion Biopharma Limited
407, Silver Radiance, Pakwan Char Rasta,
Sindhu Bhavan Road, Bodakdev,
Ahmedabad – 380054
Tel: +91 – 7948495060
E-mail: [email protected]
Website: www.infinionbiopharma.com
Registrar
BIGSHARE SERVICES PRIVATE LIMITED
1st Floor, Bharat Tin Works Building, Makwana Road,
Marol, Andheri East, Mumbai – 400 059
Tel: +91 – 22 – 6263 8200;
Email: [email protected];
Website: www.bigshareonline.com
Lead Manager(s)
- Aryaman financial services limited
We hope we are able to answer all your questions about the Infinion Biopharma IPO. If you don’t have a Demat account, open it now with Zerodha best trading app.
Disclaimer
The reference of IPO Grey Market Premium (IPO GMP) is only valid for the date specified in the header.
On the IPO Grey Market, we do not purchase or sell IPO forms.
The Kostak Rate is the profit earned by selling an IPO application (in an off-market transaction) to somebody else before the issue is allotted or listed.
Do not subscribe to an IPO based solely on the premium price, as it may alter at any time before to the listing. Only consider the fundamentals of the companies when subscribing.
The GMP rates for IPOs are based on market intelligence. Please keep in mind that these IPO GMP rates may vary by geography and market.
Note:
We do not engage in grey market trading or facilitate the purchase or sale of IPO forms. We don’t endorse such activities at all. We are sticky against such activities & never advise anyone to trade in grey market.
FAQ
Infinion Biopharma IPO Opening Date?
Infinion Biopharma IPO will open in November 2021.
Infinion Biopharma IPO Listing Date?
Infinion Biopharma IPO will list in November 2021.
Infinion Biopharma IPO GMP Today?
Infinion Biopharma IPO Grey Market Premium is INR 0.
Infinion Biopharma IPO Allotment Date?
Infinion Biopharma IPO basis of allotment will be on November 2021.
Lot size forInfinion Biopharma IPO?
Lot size for Infinion Biopharma IPO is 0.
